Skip to main content
The NCI Community Hub will be retiring in May 2024. For more information please visit the NCIHub Retirement Page:https://ncihub.cancer.gov/groups/ncihubshutdown/overview
close

CAFCW117 A Scalable, Validated Platform for Generative Lead Optimization of De Novo Molecules: Case Study in Discovery of Potent, Selective Aurora Kinase Inhibitors with Favorable Secondary Pharmacology

By Andrew Weber

Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium GlaxoSmithKline

Download (PDF)

Licensed under

Reviews

Write a review

No reviews found.